Assuming Race is at the same stage as IMU is where many investors go wrong. Race has two drugs, RC110 & RC220. RC110 is a Phase 3/4 asset that has made it all the way through to approval. RC220 is a reformulated version of RC110 designed for a much larger market. RC110 has completed more than 50 clinical trials including two modern AML trials where it performed very well in very difficult to treat patients.
The opportunity for RC220 is considerable (cardioprotection & m6A RNA) - it is an asset with multi-billion dollar market across dozens of cancers types. While RC220 is considered a pre-clinical asset from a purely regulatory perspective, it really isn’t from a risk perspective since it is designed to be identical in the patient as RC110 (it is certainly identical in all the animal studies). With RC220 you get all the benefits of a new drug and all the risk avoidance that comes with an old drug.
I am hopeful as more people understand what Race has that the SP will start to reflect the underlying value of the assets.
RAC Price at posting:
85.0¢ Sentiment: Buy Disclosure: Held
(20min delay)